Results 1 to 10 of about 29,529 (158)

Efficacy of Anakinra for Various Types of Crystal-Induced Arthritis in Complex Hospitalized Patients: A Case Series and Review of the Literature [PDF]

Mediators of Inflammation, 2015
Background. There are few data on anakinra use after failure of conventional medications for crystal-induced peripheral arthritis and/or crowned dens syndrome among complex hospitalized patients. Methods.
A. Aouba, S. Deshayes, L. Frenzel, A. Decottignies, C. Pressiat, B. Bienvenu, F. Boue, G. Damaj, O. Hermine, S. Georgin-Lavialle   +9 more
doaj   +8 more sources

CSF1R and IL1R1 inhibitors synergistically attenuate the early pathogenesis of traumatic brain injury in mice [PDF]

Neurotherapeutics
There is an unmet need in the treatment of traumatic brain injury (TBI), a leading cause of death and disability. Colony stimulating factor 1 receptor (CSF1R) and interleukin 1 receptor type 1 (IL1R1) are critical regulators of TBI-associated ...
Sudena Wang, Yong Wang, Jenny Strehle, Isa Wernersbach, Ermis Papakonstantinou, Pawit Somnuke, Katharina Ritter, Matthias Klein, Irmgard Tegeder, Michael K.E. Schäfer   +9 more
doaj   +2 more sources

Successfully Overcoming Allergy to Anakinra Through Intravenous Desensitization in a Child “Case Report” [PDF]

Case Reports in Immunology
Anakinra, a recombinant interleukin-1 (IL-1) receptor antagonist, is effective in treating autoinflammatory conditions in children; however, it may elicit a hypersensitive reaction, thus requiring desensitization.
Tariq Al Farsi
doaj   +2 more sources

Efficacy and safety of anakinra in adults presenting deteriorating respiratory symptoms from COVID-19: A randomized controlled trial.

PLoS ONE, 2022
ObjectiveWe aimed to investigate whether anakinra, an interleukin-1receptor inhibitor, could improve outcome in moderate COVID-19 patients.MethodsIn this controlled, open-label trial, we enrolled adults with COVID-19 requiring oxygen.
Alexandra Audemard-Verger, Amélie Le Gouge, Vincent Pestre, Johan Courjon, Vincent Langlois, Marc-Olivier Vareil, Mathilde Devaux, Boris Bienvenu, Vincent Leroy, Radjiv Goulabchand, Léa Colombain, Adrien Bigot, Thomas Guimard, Youcef Douadi, Geoffrey Urbanski, Jean François Faucher, Laurence Maulin, Bertrand Lioger, Jean-Philippe Talarmin, Matthieu Groh, Joseph Emmerich, Sophie Deriaz, Nicole Ferreira-Maldent, Ann-Rose Cook, Céline Lengellé, Hélène Bourgoin, Arsène Mekinian, Achille Aouba, François Maillot, Agnès Caille   +29 more
doaj   +2 more sources

The Endogenous Th17 Response in NO2-Promoted Allergic Airway Disease Is Dispensable for Airway Hyperresponsiveness and Distinct from Th17 Adoptive Transfer [PDF]

, 2013
Severe, glucocorticoid-resistant asthma comprises 5-7% of patients with asthma. IL-17 is a biomarker of severe asthma, and the adoptive transfer of Th17 cells in mice is sufficient to induce glucocorticoid-resistant allergic airway disease.
A Abe, A Duguet, A Hoshino, A Vazquez-Tello, A Vazquez-Tello, AG Besnard, AG Besnard, AI Caceres, AJ Coyle, AR Brasier, AR Sousa, AS Saffar, AT Hastie, B Korkmaz, Benjamin T. Suratt, BJ Canning, C Sutton, C Taube, D Stejskal, Daniel J. Weiss, DB Corry, DC Newcomb, DC Newcomb, DC Newcomb, DH Broide, E Goleva, F Kirstein, GJ Zijlstra, H Fujie, H Koga, H Wakashin, Hong Wei Chu, I Tillie-Leblond, J Agbetile, J Chang, J Seok, J Sunyer, J Zhao, JB Cowland, Jennifer L. Ather, JH Bates, JH Lee, JL Ather, JL Ather, John F. Alcorn, JR Karlsen, JV Fahy, K Raemdonck, K Yang, L McKinley, LA Cooney, Laura Hoyt, Lennart K. A. Lundblad, LJ Akinbami, LK Lundblad, LK Lundblad, LK Lundblad, LL Reber, M Bevelander, M Kawaguchi, M Kudo, M Leppkes, M Suzukawa, MA Willart, Matthew E. Poynter, ME Poynter, ME Poynter, ME Poynter, MH Brutsche, MH Shaw, MW Kinyanjui, N Schmitz, PA Wark, PL Delamater, PS Foster, PW Hellings, Q Wang, R He, RA Martin, Rebecca A. Martin, Rebecca Daggett, RH Wilson, S Ano, S Dragon, S Ferretti, S Haak, S Lajoie, S Molet, S Schnyder-Candrian, S Suzuki, S Wenzel, SJ Ballantyne, SM Hu, SP Chapoval, SR Hodgkins, T Li, VJ Johnson, W Al-Ramli, WP Arend, WW Lee, X Yao, XY Chi, Y Chung, Y Liu, Y Takenoue, Y Zhao, YH Wang   +106 more
core   +17 more sources

Clinical outcomes and safety of anakinra in the treatment of multisystem inflammatory syndrome in children: a single center observational study

Pediatric Rheumatology Online Journal, 2023
Background and objective Evidence for the treatment of multisystem inflammatory syndrome in children (MIS-C) is lacking. Anakinra, which targets IL-1-mediated inflammation, is reserved for refractory cases of MIS-C; however, its use in the treatment of ...
Brian L.P. Dizon, Christopher Redmond, Emily C. Gotschlich, Sangeeta Sule, Tova Ronis, Kathleen M. Vazzana, Matthew A. Sherman, Rachael Connor, Abigail Bosk, Niti Dham, Ashraf S. Harahsheh, Elizabeth Wells, Roberta DeBiasi, Hemalatha Srinivasalu   +13 more
doaj   +1 more source

Intravenous administration of anakinra in children with macrophage activation syndrome

Pediatric Rheumatology Online Journal, 2021
Background Subcutaneous anakinra is an interleukin-1 inhibitor used to treat juvenile idiopathic arthritis. Recent reports suggest anakinra can be a valuable addition to the treatment of COVID-19 associated cytokine storm syndrome and the related ...
Omkar Phadke, Kelly Rouster-Stevens, Helen Giannopoulos, Shanmuganathan Chandrakasan, Sampath Prahalad   +4 more
doaj   +1 more source

Anakinra treatment in multisystemic inflammatory syndrome in children (MIS-C) associated with COVID-19

Frontiers in Pediatrics, 2022
ObjectiveThe study aimed to report the efficacy and safety of anakinra treatment in patients with the refractory multisystemic inflammatory syndrome in children (MIS-C).MethodsThis is a cross-sectional retrospective study consisting of pediatric patients
Şengül Çaǧlayan, Hafize Emine Sönmez, Gülçin Otar Yener, Esra Baǧlan, Kübra Öztürk, Kadir Ulu, Vafa Guliyeva, Demet Demirkol, Mustafa Çakan, Semanur Özdel, Hulya Bukulmez, Nuray Aktay Ayaz, Betül Sözeri   +12 more
doaj   +1 more source

Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study

International Journal of Infectious Diseases, 2021
Objective: The aim of this study was to evaluate the efficacy of anakinra in patients who were admitted to hospital for severe COVID-19 pneumonia requiring oxygen therapy.
A. Balkhair, I. Al-Zakwani, M. Al Busaidi, A. Al-Khirbash, S. Al Mubaihsi, H. BaTaher, J. Al Aghbari, I. Al Busaidi, M. Al Kindi, S. Baawain, A. Al Alawi, A. Al Lawati, B. Al Rawahi, K. Al-Baimani, K. Al Zidi, N. Elfatih, B. Dawud, B. John, F. Rehman, F. Yousif, G. Al Khadouri, I. Saber, J. Lal, M. Gargouri, M. Al-Ward, N. AbuDraz, S. Al Ruqeishi, S. Kumar, W. Abdelmottaleb, Z. Al-Naamani, Z. Bin Nazar, O. Balkhair   +31 more
doaj   +1 more source

Impact of anakinra use on clinical outcomes in children with moderate or severe multisystem inflammatory syndrome in children: a propensity score matched retrospective cohort study

Pediatric Rheumatology Online Journal, 2023
Background The treatment of children with multisystem inflammatory syndrome in children (MIS-C) related to SARS-CoV-2 infection involves immunomodulatory therapies such as IVIG and steroids.
Esra B. Akkoyun, Zachary Most, Harita Katragadda, Andrew Yu, Lorien Nassi, Nicole Oakman, Sarah Ginsburg, Mia Maamari   +7 more
doaj   +1 more source